Volume 6.02 | Jan 20

Hematopoiesis News 6.02 January 20, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Bone Stem Cells Shown to Regenerate Bones, Cartilage in Adult Mice
A stem cell capable of regenerating both bone and cartilage has been identified in bone marrow of mice. The cells, called osteochondroreticular (OCR) stem cells, were discovered by tracking a protein expressed by the cells. Using this marker, the researchers found that OCR cells self-renew and generate key bone and cartilage cells, including osteoblasts and chondrocytes. [Press release from the Columbia University Medical Center discussing online publication in Cell] Press Release | Abstract | Graphical Abstract | Video
Request a Sample: ReproTeSR™
 
PUBLICATIONS (Ranked by impact factor of the journal)
Maintenance of Mouse Hematopoietic Stem Cells Ex Vivo by Reprogramming Cellular Metabolism
Scientists show that treatment with alexidine dihydrochloride, an antibiotic and a selective inhibitor of the mitochondrial phosphatase Ptpmt1, which is crucial for the differentiation of hematopoietic stem cells (HSCs), reprogrammed cellular metabolism from mitochondrial aerobic metabolism to glycolysis, resulting in a remarkable preservation of long-term HSCs ex vivo in part through hyperactivation of AMPK kinase. [Blood] Abstract

Notch1 Acts via Foxc2 to Promote Definitive Hematopoiesis via Effects on Hemogenic Endothelium
Investigators discovered that Notch induction enhances hematopoietic potential and promotes the specification of hemogenic endothelium in differentiating cultures of mouse embryonic stem cells, and identified Foxc2 as a highly upregulated transcript in the hemogenic endothelial population. [Blood] Abstract

Enrichment of Human Hematopoietic Stem/Progenitor Cells Facilitates Transduction for Stem Cell Gene Therapy
CD34+/CD38 cells were isolated from healthy cord blood CD34+ cells by fluorescence activated cell sorting and transduced with a lentiviral vector expressing an anti-sickling form of beta-globin. In vivo studies showed engraftment of transduced CD34+/CD38 cells when transplanted in competition with 100-fold more CD34+/CD38+ cells. [Stem Cells] Abstract

Pak2 Regulates Hematopoietic Progenitor Cell Proliferation, Survival and Differentiation
Utilizing a conditional p21-activated kinase 2 (Pak2) knock out mouse model, researchers found that disruption of Pak2 in hematopoietic stem cells induced profound leukopenia and a mild macrocytic anemia. [Stem Cells] Abstract

Enforced Expression of Hoxa5 in Hematopoietic Stem Cells Leads to Aberrant Erythropoiesis In Vivo
Scientists show that increased expression of Hoxa5 in hematopoietic stem cells (HSCs) leads to aberrant erythropoiesis in vivo. Hoxa5 differentially modifies the cell cycle of HSCs and lineage committed progenitor cells, depending on the cellular context. [Cell Cycle] Abstract

Single-Cell Mass Cytometry Reveals Intracellular Survival/Proliferative Signaling in FLT3-ITD-Mutated AML Stem/Progenitor Cells
In a primary acute myeloid leukemia (AML) sample, researchers investigated the cell responses to ex vivo stimulation with stem cell factor and BEZ235-induced inhibition of PI3K and identified activation patterns in multiple PI3K downstream signaling pathways including p-4EBP1, p-AKT, and p-S6, particularly in CD34+ subsets. [Cytometry A] Abstract

CLINICAL RESEARCH

Multicenter Experience in Hematopoietic Stem Cell Transplantation for Serious Complications of Common Variable Immunodeficiency
Investigators sought to define the outcomes of hematopoietic stem cell transplantation (HSCT) for patients with common variable immunodeficiency (CVID). Retrospective data were collected from 14 centers worldwide on patients with CVID receiving HSCT. [J Allergy Clin Immunol] Abstract

Ofatumumab In Poor-Prognosis Chronic Lymphocytic Leukemia: A Phase IV, Non­Interventional, Observational Study from The European Research Initiative on Chronic Lymphocytic Leukemia
Researchers report the largest retrospective, Phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis chronic lymphocytic leukemia. [Haematologica] Abstract

ASXL1 Mutations In Younger Adult Patients with Acute Myeloid Leukemia: A Study of The German-Austrian Acute Myeloid Leukemia Study Group
Investigators studied 1696 patients with acute myeloid leukemia for ASXL1 mutations and identified these mutations in 103 patients. ASXL1 mutations were associated with older age, male sex, secondary acute myeloid leukemia, and lower values for bone marrow and circulating blasts. [Haematologica] Abstract

Learn More: StemSpan™ Myeloid Expansion Supplement
 
REVIEWS
Preleukemia: The Normal Side of Cancer
The authors define the preleukemic state. They aim at increasing awareness and research in the field of preleukemia that will nurture targeted therapy for the earlier steps of leukemia evolution. [Curr Opin Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
 
INDUSTRY NEWS
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate Adcetris and Bristol-Myers Squibb’s immunotherapy Opdivo in two planned Phase I/II clinical trials. [Bristol-Myers Squibb Company] Press Release

Bellicum Pharmaceuticals Announces Successful Dosing of First Patient Cohort with BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant
Bellicum Pharmaceuticals, Inc. announced that the first cohort of patients in the BP-004 trial has completed dosing with the Company’s genetically engineered donor T cells (BPX-501), after receiving a partial T depleted haplo-identical allogeneic hematopoietic stem cell transplant. [Bellicum Pharmaceuticals, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cellular Therapy 2015 – 8th International Symposium on the Clinical Use of Cellular Products
March 19-20, 2015
Erlangen, Germany

NEW 2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT)
October 15-18, 2015
Antalya, Turkey

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Director (California Institute for Regenerative Medicine)

NEW Postdoctoral Fellow – Stem Cell/Translational Medicine (Rutgers New Jersey Medical School)

Postdoctoral Fellow – Hematopoiesis and Stem Cell Biology (Lund University)

Postdoctoral Research Scientist – Human T Cell Leukemia (Washington University School of Medicine)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

PhD Student – Experimental Leukemia Research (University Children’s Hospital Basel)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us